Everolimus FDA approval date

The FDA approved Everolimus (Afinitor) on 30 Mar 2009.

FDA approval date
30 Mar 2009

Drug identity checked against registry records

Also recorded as Afinitor

Included trials

TrialSponsorPhaseStatusPrimary completion
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsNCT06943755ExelixisPhase 2, Phase 3Recruiting2029-06-30Estimated

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2009-03-30DayEverolimusFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA022334", "applicant_as_listed_by_fda": "NOVARTIS", "brand_names": ["AFINITOR"], "active_ingredients": ["EVEROLIMUS"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20090330", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026